News
Alvotech, Teva Announce US FDA Approval Of SELARSDI, Biosimilar To Stelara
16 Apr 24
News, FDA
Alvotech Receives FDA Approval For Selarsdi For Moderate To Severe Plaque Psoriasis
16 Apr 24
Biotech, News, FDA, General
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
25 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Alvotech Announces Increased The Company's Share Capital By An Amount Of $130K By Issuing 13M Ordinary Shares
22 Mar 24
News
Barclays Maintains Overweight on Alvotech, Raises Price Target to $20
22 Mar 24
News, Price Target, Analyst Ratings
Alvotech FY 2023 GAAP EPS $(2.43) Misses $(1.07) Estimate, Sales $93.400M Miss $112.470M Estimate
20 Mar 24
Earnings, Earnings Misses, News
Earnings Scheduled For March 20, 2024
20 Mar 24
Earnings
Why Is Generic Drugs Player Teva Pharma Stock Trading Higher Today?
26 Feb 24
Large Cap, News, Health Care, FDA, Movers, General
Alvotech Has Settled With Johnson & Johnson For Certain Markets For AVT04, A Biosimilar To Stelara (Ustekinumab), Market Entry Of AVT04 In Canada Is Expected In Q1 2024, With May 2024 For Japan, And Later July 2024 For First European Markets
15 Feb 24
News, Health Care, General
Press releases
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
30 Apr 24
Press Releases
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)
30 Apr 24
Press Releases
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)
24 Apr 24
Health Care, Press Releases
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
16 Apr 24
Press Releases
Alvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024
3 Apr 24
News, Press Releases
Alvotech Announces Increase in Number of Own Shares
22 Mar 24
Press Releases
Alvotech Reports Financial Results for Full Year 2023 and Provides a Business Update
20 Mar 24
Earnings, Press Releases
Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
5 Mar 24
News, Press Releases
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
26 Feb 24
Press Releases
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
23 Feb 24
Health Care, Press Releases
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
23 Feb 24
Press Releases
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
15 Feb 24
News, Financing, Press Releases